Correlation of KRAS status with clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated first-line with FOLFOX6+cetuximab (FX plus C) or FOLFIRI plus cetuximab (FF plus C): The CECOG/CORE1.2.001 trial

被引：0
|
作者：
Koza, I., Sr. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Wrba, F. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Vrbanec, D. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Ocvirk, J. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Ciuleanu, T. E. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Beslija, S. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Papamichael, D. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Messinger, D. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Zielinski, C. C. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Brodowicz, T. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
机构：
[1] NCI, Bratislava, Slovakia
[2] Med Univ Vienna, Vienna, Austria
[3] Univ Hosp Rebro, Zagreb, Croatia
[4] Inst Oncol, Ljubljana, Slovenia
[5] Univ Med Cluj Napoca, Cluj Napoca, Romania
[6] Univ Sarajevo, Ctr Clin, Sarajevo 71000, Bosnia & Herceg
[7] Bank Cyprus Oncol Ctr, Nicosia, Cyprus
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4055
引用
收藏
页数：2
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS ANALYSIS OF PANITUMUMAB plus FOLFOX COMPARED TO CETUXIMAB plus FOLFIRI AS FIRST-LINE TREATMENT FOR PATIENTS WITH WILD-TYPE (WT) RAS (EXONS 2, 3, AND 4 OF KRAS AND NRAS) METASTATIC COLORECTAL CANCER (MCRC) IN COLOMBIA
    Vargas-Valencia, J.
    Garcia Perlaza, J.
    VALUE IN HEALTH, 2015, 18 (07) : A460 - A460
  • [42] Efficacy and safety of first-line cetuximab plus FOLFIRI in older and younger patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the CRYSTAL study.
    Van Cutsem, Eric
    Kohne, Claus-Henning
    Folprecht, Gunnar
    Guenther, Silke
    Beier, Frank
    Papamichael, Demetris
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [43] CETUXIMAB PLUS XELIRI VERSUS CETUXIMAB PLUS XELOX AS FIRST-LINE TREATMENT FOR PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC): ANALYSIS OF THE RANDOMIZED TRIAL OF THE GERMAN AIO CRC STUDY GROUP: KRK-0204
    Stintzing, S.
    Jung, A.
    Vehling-Kaiser, U.
    Stauch, M.
    Hass, H.
    Dietzfelbinger, H.
    von Weikersthal, L. Fischer
    Moosmann, N.
    Kirchner, T.
    Heinemann, V.
    ANNALS OF ONCOLOGY, 2010, 21 : 189 - 190
  • [44] Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
    Bokemeyer, C.
    Bondarenko, I.
    Hartmann, J. T.
    de Braud, F.
    Schuch, G.
    Zubel, A.
    Celik, I.
    Schlichting, M.
    Koralewski, P.
    ANNALS OF ONCOLOGY, 2011, 22 (07) : 1535 - 1546
  • [45] Randomized trial comparing cetuximab plus XELIRI versus cetuximab plus XELOX as first line treatment of patients with metastatic colorectal cancer (mCRC): A study of the german AIO CRC study group
    Heinemann, V.
    von Weikersthal, L. Fischer
    Vehling-Kaiser, U.
    Stauch, M.
    Oruzio, D.
    Schulze, M.
    Hass, H. G.
    Weiss, J.
    Dietzfelbinger, H.
    Moosmann, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [46] Cetuximab plus chemotherapy as first-line treatment for metastatic colorectal cancer: Effect of KRAS mutation on treatment efficacy in Taiwanese patients
    Chen, M. C.
    Chiang, F. F.
    Wang, H. M.
    NEOPLASMA, 2013, 60 (05) : 561 - 567
  • [47] Association of FcgRIIa and FcgRIIIa polymorphisms and kras mutations with clinical outcome in patients with metastatic colorectal cancer treated with cetuximab plus irinotecan
    Bibeau, F.
    Crapez, E.
    Di Fiore, F.
    Thezenas, S.
    Sabourin, J.
    Lamy, A.
    Frebourg, T.
    Michel, P.
    Ychou, M.
    Boissiere, F.
    ANNALS OF ONCOLOGY, 2008, 19 : 27 - 27
  • [48] Association of genetic variations in genes implicated in the axis with outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with cetuximab plus chemotherapy.
    Miyamoto, Yuji
    Stintzing, Sebastian
    Heinemann, Volker
    Zhang, Wu
    Cao, Shu
    Okazaki, Satoshi
    Berger, Martin D.
    Suenaga, Mitsukuni
    Schirripa, Marta
    Soni, Shivani
    Matsusaka, Satoshi
    Ning, Yan
    Yang, Dongyun
    Gopez, Roel
    Melendez, Elizabeth
    Hanna, Diana L.
    Barzi, Afsaneh
    Baba, Hideo
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [49] Quality of life analysis in patients with RAS wild-type metastatic colorectal cancer treated with first-line FOLFIRI plus cetuximab in the CRYSTAL study
    Yamaguchi, K.
    Ando, M.
    Ooki, A.
    Beier, F.
    Guenther, S.
    Von Hohnhorst, P.
    Van Cutsem, E.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S370 - S371
  • [50] Results of a phase II trial of cetuximab plus XELIRI as first-line therapy of patients with advanced and/or metastatic colorectal cancer
    Cartwright, T. H.
    Kuefler, P.
    Cohn, A.
    Hyman, W.
    Yoffe, M.
    Boehm, K. A.
    Ilegbodu, D.
    Asmar, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345